Trial NCT04341389
Publication Zhu F, The Lancet, 2020.
Primary outcome on the report: Incidence of adverse reactions within 14 days after the injection.Geometric mean titres (GMTs) of RBD-specific ELISAantibody responses and neutralising antibody responsesagainst live virus or pseudovirus at day 28 post vaccination.